title: Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer.
abstract: BACKGROUND
  To assess the efficacy of concurrent chemoradiotherapy (CCRT) with daily low-dose cisplatin (CDDP) plus weekly docetaxel (DTX) for patients with T2N0 glottic cancer.
  
  
  METHODS
  Between January 2004 and December 2013, 62 treatment-naive patients with histologically proven T2N0 glottic cancer were treated with concurrent chemoradiotherapy. Radiation therapy (RT; 2 Gy daily fractions up to a total dose of 66 Gy) was administered in combination with daily low-dose CDDP (6 mg/m2, five times a week), plus weekly DTX (10 mg/m2) for up to 4 weeks from the commencement of RT.
  
  
  RESULTS
  Median duration of follow-up was 70 months. The actuarial 3-year and 5-year overall survival rates were 95% and 93%. The 3-year and 5-year cause-specific survival rates were both 100%. The actuarial 3-year and 5-year local control rates were 94% and 94%, respectively. Hematologic toxicity (neutoropenia of severity ≥ Grade 3) was observed in 8% of the patients, and non-hematologic toxicity (radiation mucositis of severity ≥ Grade 3) developed in one patient (2%). Radiation dermatitis of severity ≥ Grade 3 and laryngeal necrosis developed in one patient.
  
  
  CONCLUSIONS
  CCRT with weekly DTX and low-dose CDDP appears to be a practical and safe modality and is expected to improve local control.
  
  
  BACKGROUND
  UMIN000025046 . Registered 1 October 2015, retrospectively registered.
authors.affiliation: Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan. junsaito@gunma-u.ac.jp.
authors.forename: Jun-Ichi
authors.initials: JI
authors.lastname: Saitoh
authors.affiliation: Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Shirai
authors.affiliation: Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
authors.forename: Masumi
authors.initials: M
authors.lastname: Imaeda
authors.affiliation: Gunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Musha
authors.affiliation: Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
authors.forename: Takanori
authors.initials: T
authors.lastname: Abe
authors.affiliation: Department of Otolaryngology-Head & Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
authors.forename: Masato
authors.initials: M
authors.lastname: Shino
authors.affiliation: Department of Otolaryngology-Head & Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Takayasu
authors.affiliation: Department of Otolaryngology-Head & Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
authors.forename: Katsumasa
authors.initials: K
authors.lastname: Takahashi
authors.affiliation: Department of Otolaryngology-Head & Neck Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Chikamatsu
authors.affiliation: Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371-8511, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakano
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D019583:Dose Fractionation, Radiation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin
keywords: Chemotherapy; Laryngeal cancer; Radiation therapy; Voice preservation